Ken Fisher's CRL Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 1,002 shares of Charles River Laboratories International, Inc. (CRL) worth $227,394, representing 0.00% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2014, adding 161,112 shares. Largest reduction occurred in Q2 2025, reducing 255,223 shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +1,002 | New Buy | 1,002 | $226.94 |
| Q2 2025 | -255,223 | Sold Out | 0 | $0.00 |
| Q1 2025 | +22,905 | Add 9.86% | 255,223 | $150.52 |
| Q4 2024 | +47,626 | Add 25.79% | 232,318 | $184.60 |
| Q3 2024 | +1,586 | Add 0.87% | 184,692 | $196.97 |
| Q2 2024 | -1,549 | Reduce 0.84% | 183,106 | $206.58 |
| Q1 2024 | -1,771 | Reduce 0.95% | 184,655 | $270.95 |
| Q4 2023 | -2,274 | Reduce 1.21% | 186,426 | $236.40 |
| Q3 2023 | -13,667 | Reduce 6.75% | 188,700 | $195.98 |
| Q2 2023 | -13,868 | Reduce 6.41% | 202,367 | $210.25 |
| Q1 2023 | -34,905 | Reduce 13.90% | 216,235 | $201.82 |
| Q4 2022 | +10,381 | Add 4.31% | 251,140 | $217.90 |
| Q3 2022 | -12,266 | Reduce 4.85% | 240,759 | $196.80 |
| Q2 2022 | +4,631 | Add 1.86% | 253,025 | $213.97 |
| Q1 2022 | -3,268 | Reduce 1.30% | 248,394 | $283.97 |
| Q4 2021 | +8,521 | Add 3.50% | 251,662 | $376.78 |
| Q3 2021 | +7,909 | Add 3.36% | 243,141 | $412.67 |
| Q2 2021 | -2,896 | Reduce 1.22% | 235,232 | $369.92 |
| Q1 2021 | -3,411 | Reduce 1.41% | 238,128 | $289.83 |
| Q4 2020 | -8,586 | Reduce 3.43% | 241,539 | $249.86 |
| Q3 2020 | -21,479 | Reduce 7.91% | 250,125 | $226.45 |
| Q2 2020 | -22,107 | Reduce 7.53% | 271,604 | $174.35 |
| Q1 2020 | -53,851 | Reduce 15.49% | 293,711 | $126.21 |
| Q4 2019 | -90,809 | Reduce 20.72% | 347,562 | $152.76 |
| Q3 2019 | -32,970 | Reduce 6.99% | 438,371 | $132.37 |
| Q2 2019 | +29,980 | Add 6.79% | 471,341 | $141.90 |
| Q1 2019 | +5,690 | Add 1.31% | 441,361 | $145.25 |
| Q4 2018 | +56,394 | Add 14.87% | 435,671 | $113.18 |
| Q3 2018 | +14,538 | Add 3.99% | 379,277 | $134.54 |
| Q2 2018 | -13,881 | Reduce 3.67% | 364,739 | $112.26 |
| Q1 2018 | -57,408 | Reduce 13.17% | 378,620 | $106.74 |
| Q4 2017 | -16,128 | Reduce 3.57% | 436,028 | $109.45 |
| Q3 2017 | -5,416 | Reduce 1.18% | 452,156 | $108.02 |
| Q2 2017 | -6,140 | Reduce 1.32% | 457,572 | $101.15 |
| Q1 2017 | -26,392 | Reduce 5.38% | 463,712 | $89.95 |
| Q4 2016 | -18,556 | Reduce 3.65% | 490,104 | $76.19 |
| Q3 2016 | -7,468 | Reduce 1.45% | 508,660 | $83.34 |
| Q2 2016 | -13,706 | Reduce 2.59% | 516,128 | $85.55 |
| Q1 2016 | +13,339 | Add 2.58% | 529,834 | $80.47 |
| Q4 2015 | +33,596 | Add 6.96% | 516,495 | $80.39 |
| Q3 2015 | -25,417 | Reduce 5.00% | 482,899 | $63.52 |
| Q2 2015 | +105,850 | Add 26.30% | 508,316 | $70.34 |
| Q1 2015 | +19,364 | Add 5.05% | 402,466 | $79.29 |
| Q4 2014 | +14,894 | Add 4.04% | 383,102 | $63.64 |
| Q3 2014 | -3,616 | Reduce 0.97% | 368,208 | $59.74 |
| Q2 2014 | +161,112 | Add 76.46% | 371,824 | $53.52 |
| Q1 2014 | +156,432 | Add 288.19% | 210,712 | $60.34 |
| Q4 2013 | +1,880 | Add 3.59% | 54,280 | $53.04 |
| Q3 2013 | +52,400 | New Buy | 52,400 | $46.26 |
Ken Fisher's Charles River Laboratories International Investment FAQs
Ken Fisher first purchased Charles River Laboratories International, Inc. (CRL) in Q3 2013, acquiring 52,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Charles River Laboratories International, Inc. (CRL) for 49 quarters since Q3 2013.
Ken Fisher's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q2 2014, adding 371,824 shares worth $19.9 M.
According to the latest 13F filing for Q2 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 1,002 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $227,394.
As of the Q2 2026 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Charles River Laboratories International, Inc. (CRL) was 529,834 shares, as reported at the end of Q1 2016.